Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
The use of circulating tumor DNA in patients with advanced colorectal cancer may provide early insight into who is and is not responding to treatment, according to an expert from Weill Cornell Medicine.
Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.
In this installment of Clinical Quandaries, Bendu Konneh, BS, and colleagues present a case of a 21-year-old male with a 4-month history of progressive swelling in the right testicle.
This review article written by Nikia R. McFadden, MD, MAS, et al, discusses which therapies are best to treat unresectable colorectal liver metastases.
At the 2022 ASCO Annual Meeting, Christine Parseghian, MD, reviewed results from a phase 2 trial assessing efficacy of panitumumab plus or minus trametinib in patients with RAS/BRAF wild-type colorectal cancer and compared EGFR rechallenge strategies with available agents in the third-line setting.
This study presents a male breast cancer case with a germline BRCA2 mutation and discusses the epidemiologic, pathologic, and clinical characteristics along with treatment and follow-up recommendations in view of our recent understanding of the disease.
Pooling data with other radiation trials, looking more closely at central non-small cell lung cancer, and exploring secondary outcomes represent the next steps in terms of analyzing stereotactic body radiation (SBRT) vs conventional hypofractionated radiotherapy (CRT), according to Anand Swaminath, MD.
Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
COVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.
Panelists discuss how the treatment landscape for patients with transplant-ineligible/deferred newly diagnosed multiple myeloma (NDMM) is expected to evolve, with considerations for optimizing therapeutic approaches based on emerging data from novel drug combinations and treatment strategies.
In an interview with ONCOLOGY®, David Hughes PharmD, BCOP, and Jessica Freydman, PharmD, offers a comprehensive review of real-world treatment considerations of tepotinib as therapy for patients with metastatic non–small cell lung cancer that have MET exon14 skipping mutations.
Danazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.
The latest podcast episode of Oncology Peer Review On-The-Go features a conversation with Tzvia Bader and Karine Perreault on TrialJectory’s platform, which seeks to guide patients with cancer on their treatment journey.
Experts discuss the process of assessing decision-making capacity in patients with cancer.